Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
AFP13h
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
Hosted on MSN1d
What Is the Difference Between Dandruff and Dry Scalp?
Medically reviewed by William Truswell, MD Dandruff and dry scalp are two conditions that cause similar symptoms. Dandruff is ...
The Healthy on MSN2d
What’s That Rash? How to ID 14 of the Most Common Skin Irritations
Feeling a little itchy? Here's how to recognize the most commonly undiagnosed skin irritations, including the one you may ...
Atopic eczema cases rise, affecting quality of life and health
Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...